We read with interest the article published in the January 2009 issue of this journal entitled 'Variation near complement factor I is associated with risk of advanced AMD' . 1 The complement factor I (CFI) gene has been the focus of study within our own UK cohort of age-related macular degeneration patients and controls. Soon after the publication of the seminal papers implicating the complement factor H (CFH) gene, 2-4 we conducted a case-control study of this gene involving 190 DNA samples from patients and 179 control samples. This cohort has been earlier described. 5 Briefly, all participants were white, aged more than 55 years, and ascertained through ophthalmic research clinics in the Southampton locality. All participants provided informed consent and were examined by an experienced retinal specialist. All patients had an AREDS classification of 2 or greater. Control samples were either spouses or partners of patients with disease or those who presented at the eye clinics for an unrelated eye disease. Summary demographics of the cohort used are detailed in Table 1 .
After correction for multiple testing, our results were of marginal significance and so of somewhat unclear relevance to AMD when appraised in isolation. However, in light of results published by Fagerness et al in a larger sample (1228 cases and 825 controls), the data are of renewed interest and are presented here in support of their recent finding.
We genotyped six SNPs in the CFI region (Figure 1 ), four of which were also genotyped by Fagerness et al including their most significant SNP rs10033900 and its partner in the most significant haplotype rs13117504. Genotyping was carried out by KBioscience (Hoddesdon, Hertfordshire, UK) using KASPar chemistry (http://www.kbioscience. co.uk/genotyping/genotyping_chemistry.html).
Data were analysed using PLINK software (Version 1.06, http://pngu.mgh.harvard.edu/purcell/plink/). 7 A high genotyping rate (498.6%) was achieved and all SNPs conformed to HardyWeinberg equilibrium as tested in the control samples only. Results of our single SNP analysis are provided in Table 2 . Although four SNPs are nominally significant in this initial analysis, no single SNP maintains marginal significance after (conservative) Bonferroni correction for multiple testing. Furthermore, these four SNPs have very similar minor allele frequencies and are likely to be genetically hitchhiking with one another. Of the four SNPs common to both studies, two SNPs found to be significant in the US study are not formally significant in our sample. However, it is interesting that rs11726949 has a suggestive P-value (0.09) and a very similar odds ratio (OR) in both studies (OR US ¼1.63, OR UK ¼1.64). The other two SNPs common to both studies (rs6854876 and rs13117504) show independent significance across samples with highly concordant estimates of OR.
Using the Haploview software (version 4.1, http://www.broad.mit. edu/mpg/haploview/) 6 and the solid spine of LD method (D¢40.8), we estimated haplotype block boundaries in our sample and analysed association between haplotypes and disease status (Table 3) . For ease of comparison between studies, we also analysed the haplotype investigated by Fagerness et al (although this haplotype actually straddles the two blocks identified in our data). Two complementary haplotypes (GCAG and TGGC) account for approximately 95% of chromosome variation across block 1. Both are significantly associated with disease status in our data with the GCAG haplotype conferring protection (OR¼0.69) and its complement TGGC conferring risk (OR 1.64). Haplotype 'TT' from block 2 is statistically significant (P¼0.02) with an OR of 2.15. This is of particular interest as this haplotype contains the most significant SNP identified by Fagerness et al, but neither of the SNPs reached formal significance when examined singularly within our sample. Similar to the single SNP analyses, the data from the two-SNP haplotype used by Fagerness et al are highly comparable between studies given the larger sample has much greater power. Our results are based on an independent cohort ascertained from ophthalmic clinics in the Southampton region of the United Kingdom. Despite being based on a much smaller sample size, our data support the findings of Fagerness et al, implicating genomic variation in the region of the CFI gene with AMD disease susceptibility. These results enforce the suggestion that this region warrants comprehensive evaluation. 
